Two-Year Results After AAV2-Mediated Gene Therapy for Choroideremia: The Alberta Experience
- 22 June 2018
- journal article
- research article
- Published by Elsevier BV in American Journal of Ophthalmology
- Vol. 193, 130-142
- https://doi.org/10.1016/j.ajo.2018.06.011
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Long-Term Effect of Gene Therapy on Leber’s Congenital AmaurosisNew England Journal of Medicine, 2015
- High-Resolution Adaptive Optics Retinal Imaging of Cellular Structure in ChoroideremiaInvestigative Ophthalmology & Visual Science, 2014
- AUTOMATED IMAGE ALIGNMENT AND SEGMENTATION TO FOLLOW PROGRESSION OF GEOGRAPHIC ATROPHY IN AGE-RELATED MACULAR DEGENERATIONRetina, 2014
- Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trialThe Lancet, 2014
- Functional expression of Rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivoJournal of Molecular Medicine, 2013
- Retinal Gene Therapy Coming of AgeHuman Gene Therapy, 2013
- Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvementProceedings of the National Academy of Sciences of the United States of America, 2013
- Transition Zones between Healthy and Diseased Retina in Choroideremia (CHM) and Stargardt Disease (STGD) as Compared to Retinitis Pigmentosa (RP)Investigative Ophthalmology & Visual Science, 2011
- Remodeling of the Human Retina in Choroideremia: Rab Escort Protein 1 (REP-1) MutationsInvestigative Ophthalmology & Visual Science, 2006